Completed

An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Eye Diseases+1

+ Macular Degeneration

+ Retinal Degeneration

Over 50 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: July 2004
See protocol details

Summary

Principal SponsorEyetech Pharmaceuticals
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 2004

Actual date on which the first participant was enrolled.

To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.

Official TitleAn Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD) 
Principal SponsorEyetech Pharmaceuticals
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesMacular DegenerationRetinal DegenerationRetinal Diseases

Criteria

Inclusion Criteria: * Best corrected visual acuity in the study eye between 20/40 and 20/320. * Subfoveal choroidal neovascularization, secondary to age related macular degeneration, with a total lesion size \[including blood, scar/atrophy \& neovascularization\] of \< 12 total disc areas, of which at least 50% must be active CNV. * Any subretinal hemorrhage must comprise no more than 50% of total lesion size. General Criteria: * Patients of either gender, aged greater than 50 years. * Women must be using two forms of effective contraception, or be post-menopausal for at least 12 months prior to study entry, or surgically sterile. If of child-bearing potential, a serum pregnancy test must be performed within 48 hours prior to treatment and the result made available prior to treatment initiation. The two forms of effective contraception must be implemented during the study and for at least 60 days following the last dose of test medication. * Written informed consent. Exclusion Criteria: * Any subfoveal scarring or atrophy and no more than 25% of the total lesion size may be made up of scarring or atrophy. * Patients who are eligible for PDT with Visudyne * Patients who are eligible for any other of the Sponsor's ongoing AMD studies still open to enrollment.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 20 locations

Suspended

Doheny Eye Institute

Los Angeles, United StatesSee the location
Suspended

Connecticut Retina Consultants, L.L.C.

Bridgeport, United States
Suspended

New England Retina Associates

Hamden, United States
Suspended

Retina Health Center

Fort Myers, United States
Completed20 Study Centers